Adinazolam sustained-release treatment of panic disorder: a double-blind study

• Published in: Journal of clinical psychopharmacology Vol. 14; no. 4; p. 255
• Main Authors: Davidson, J R, Beitman, B, Greist, J H, Maddock, R J, Lewis, C P, Sheridan, A Q, Carter, C, Krishnan, K R, Liebowitz, M R, Haack, D G
• Format: Journal Article
• Language: English
• Published: United States 01.08.1994
• Subjects: Adult; Agoraphobia - drug therapy; Agoraphobia - psychology; Anti-Anxiety Agents; Antidepressive Agents - administration & dosage; Antidepressive Agents - adverse effects; Benzodiazepines - administration & dosage; Benzodiazepines - adverse effects; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Panic Disorder - drug therapy; Panic Disorder - psychology; Personality Assessment - statistics & numerical data; Personality Inventory - statistics & numerical data; Psychometrics; Treatment Outcome
• ISSN: 0271-0749
• DOI: 10.1097/00004714-199408000-00005

Two hundred six outpatients with panic disorder and agoraphobia were randomly assigned to receive 4 weeks of treatment with placebo or sustained-release adinazolam under double-blind conditions. Eighty-eight percent of patients receiving drug and 85% of patients receiving placebo remained in the study at week 4. This report describes the "intent-to-treat" analysis of 202 patients who made at least one follow-up visit after randomization at baseline. On the basis of the Clinical Global Impressions-Improvement Scale, 69.7% of the adinazolam-treated patients were much or very much improved compared with 39.6% of the placebo-treated patients at week 4 or end-point (p = 0.0001). At week 4, panic attacks were completely blocked in 57.1% of adinazolam-treated patients and in 39.2% of the placebo-treated patients (p = 0.009). Adinazolam sustained-release treatment was statistically more effective than placebo treatment on measures of global improvement, number of panic attacks, SCL-90 phobia severity, main phobia severity, and anticipatory and general anxiety. No drug-placebo differences were found for overall self-rated phobia severity, unexpected or situational panic attacks, or for work, family, or social disability.